Compare Electronic Arts Inc. (EA) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Electronic Arts (EA) trades at $207.31, up 0.32% on the day, with a bullish technical signal from moving averages and strong support at $205. The company reported Q4 2025 EPS beat but Q1 2026 miss, with revenue stable around $7.5B and a net income margin of 11.78%. Recent launches like EA SPORTS College Football 27 and UFC 6 highlight ongoing product momentum, while a potential $55B acquisition by Saudi investors adds strategic intrigue.

Outlook remains mixed: high valuation ratios (P/E 59.05) suggest premium pricing, but robust cash flow and dividend payments support shareholder returns. Key risks include earnings volatility and competitive pressures in gaming. Analyst consensus leans Hold (56.06%), indicating cautious optimism amid execution uncertainties.

Regeneron (REGN) trades at $676.59, up 3.12% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The stock shows robust fundamentals with a 29.65% net income margin and $4.50B net income in 2025, supported by positive regulatory news including FDA acceptance of cemdisiran for gMG. Analyst consensus is strongly bullish with a $764.50 price target.

Outlook remains positive given earnings beats and regulatory tailwinds, but risks include dependence on key drugs and market volatility. The stock offers growth potential with a reasonable P/E of 16.22, though investors should monitor competitive pressures and pipeline execution.